CCR5 antagonism in HIV infection: current concepts and future opportunities
TJ Wilkin, RM Gulick - Annual review of medicine, 2012 - annualreviews.org
CCR5 antagonists inhibit HIV-1 entry by blocking the interaction of HIV-1 with the CCR5
cellular receptor. In patients with established HIV-1 infection, some viral strains use an
alternative coreceptor for HIV-1 entry, CXCR4; CCR5 antagonists are not effective in
patients harboring these viral strains. Coreceptor tropism testing of viral strains in an
individual patient is necessary prior to treating with a CCR5 antagonist. There is one CCR5
antagonist, maraviroc, that is FDA-approved for treatment of HIV-1 infection. This drug is …
cellular receptor. In patients with established HIV-1 infection, some viral strains use an
alternative coreceptor for HIV-1 entry, CXCR4; CCR5 antagonists are not effective in
patients harboring these viral strains. Coreceptor tropism testing of viral strains in an
individual patient is necessary prior to treating with a CCR5 antagonist. There is one CCR5
antagonist, maraviroc, that is FDA-approved for treatment of HIV-1 infection. This drug is …